Fate Therapeutics
FATE
248 hedge funds and large institutions have $7.95B invested in Fate Therapeutics in 2020 Q4 according to their latest regulatory filings, with 67 funds opening new positions, 72 increasing their positions, 94 reducing their positions, and 30 closing their positions.
127% more capital invested
Capital invested by funds: $3.51B → $7.95B (+$4.44B)
123% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 30
75% more funds holding in top 10
Funds holding in top 10: 8 → 14 (+6)
18% more funds holding
Funds holding: 211 → 248 (+37)
1.55% less ownership
Funds ownership: 101.12% → 99.57% (-1.5%)
12% less call options, than puts
Call options by funds: $17.2M | Put options by funds: $19.5M
23% less repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 94
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$90.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$72.9M |
| 3 |
LPC
Lone Pine Capital
Greenwich,
Connecticut
|
+$54.9M |
| 4 |
Morgan Stanley
New York
|
+$42.9M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$39.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$92.1M |
| 2 |
GH
Grosvenor Holdings
Chicago,
Illinois
|
-$54.4M |
| 3 |
State Street
Boston,
Massachusetts
|
-$49.4M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$45.1M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$42.4M |
FATE Hedge Fund Activity: Q4 2020 in Review
248 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q4 2020, worth a combined $7.95B — up 127% from $3.51B a quarter earlier.
Buyers outnumbered sellers: 67 funds opened new FATE positions and 30 closed out — a net gain of 37 holders — while 72 added to existing stakes and 94 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $90.8M. The largest seller was Citadel Advisors, cutting an estimated $92.1M.
- 248 institutional investors held Fate Therapeutics (FATE) as of Q4 2020, up from 211 in Q3 2020.
- Funds reported $7.95B of Fate Therapeutics stock for Q4 2020, up 127% quarter-over-quarter.
- 67 funds opened new Fate Therapeutics positions in Q4 2020 and 30 closed out, a net change of +37 holders.
- The largest Fate Therapeutics buyer in Q4 2020 was ARK Investment Management, an estimated $90.8M added.
- The largest Fate Therapeutics seller in Q4 2020 was Citadel Advisors, an estimated $92.1M sold.
Based on aggregated 13F filings for Q4 2020.